This compound is a bis-protected imidazole-containing intermediate featuring two pyrrolidine rings each bearing a tert-butoxycarbonyl (Boc) protecting group. It is primarily utilized in the synthesis of compounds for hepatitis C virus (HCV) research.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1007882-23-6
3-(4-Methoxy-phenoxy)-propylamine
pharmaceutical intermediate
4-Chloro-2-methoxypyridine-3-carbaldehyde
pharmaceutical intermediate
2-Methoxy-4-methylpyridine
pharmaceutical intermediate
Tert-Butyl[3-[2-(diphenylphosphinoyl)ethylidene]-4-methylenecyclohexyloxy]dimethylsilane
pharmaceutical intermediate
Daclatasvir
pharmaceutical raw material
Daclatasvir dihydrochloride
pharmaceutical raw material
2-((2S)-Pyrrolidin-2-yl)-5-(4-(4-(2-((2S)-pyrrolidin-2-yl)-1H-imidazol-5-yl)phenyl)phenyl)-1himidazole tetrahydrochloride
pharmaceutical intermediate
tert-butyl (2S)-2-[5-[4-[4-[2-[(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carboxylate
WPMTYMFNINZZHE-KYJUHHDHSA-N
CC(C)(C)OC(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)OC(C)(C)C